Nora Navone, MD, PhD
FGFR Inhibition to Develop Effective Combination Therapies Fibroblast growth factor (FGF) and its receptor (FGFR) form a protein-protein complex that has been implicated in prostate tumor cells as a pathway...Read More
Andreas Varkaris
Understanding the molecules and mechanisms that contribute to prostate cancer progression and resistance to therapies will help researchers to design better treatments for patients. Dr. Andreas Varkaris is studying how...Read More
James Marshall, PhD
Diet and Progression of Prostate Cancer among Men on Active Surveillance Active surveillance is a clinical program for men diagnosed with very early (low grade and stage) prostate cancer who...Read More
Barry Taylor
One of the challenges in prostate cancer care is distinguishing men with high-risk disease requiring aggressive therapy from those who can be managed with active surveillance. The work’s proposal is...Read More
Abhishek Srivastava
Dr. Srivastava is studying malignant cells from different regions of the prostate to analyze their genetic relationships with the aim to answer the following questions. Is one patient’s prostate cancer...Read More
Timothy Showalter
For prostate cancer patients at higher risk of recurrence after radical prostatectomy (RP), early adjuvant radiation therapy (RT) has been shown in randomized trials to improve PSA-relapse free survival, metastasis-free...Read More
Yusuke Shiozawa
It is unclear why prostate cancer selectively metastasizes to and proliferates in bone. Although multiple factors are thought to be involved in the dissemination process of disseminated tumor cells (DTCs)...Read More
Sameek Roychowdhury
Dr. Roychowdhury works to underline and identify genetic alterations, which is a major step forward in personalizing cancer treatments. This work will provide a greater understanding of the totality of...Read More
Sumit Subudhi
Ipilimumab is a cancer immunotherapy that has recently been FDA approved for treatment of metastatic melanoma. A phase 3 clinical trial in metastatic prostate cancer patients failed to demonstrate an...Read More
Dana Rathkopf
The success of next-generation androgen receptor (AR) inhibitors for treatment of castration-resistant prostate cancer validates the critical role played by AR in advanced disease. Unfortunately, patients develop resistance to AR-targeted...Read More